These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17224217)

  • 1. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients.
    Yao X; Zheng B; Zhou J; Xu DZ; Zhao K; Sun SH; Yuan ZH; Wen YM
    Vaccine; 2007 Feb; 25(10):1771-9. PubMed ID: 17224217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine.
    Wang XY; Zhang XX; Yao X; Jiang JH; Xie YH; Yuan ZH; Wen YM
    Vaccine; 2010 Nov; 28(51):8169-74. PubMed ID: 20937312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B].
    Wang XY; Yao X; Guo LM; Xu LF; Shen XL; Xu DZ; Zhao K; Wen YM
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):718-20. PubMed ID: 19785971
    [No Abstract]   [Full Text] [Related]  

  • 4. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.
    Böcher WO; Galun E; Marcus H; Daudi N; Terkieltaub D; Shouval D; Löhr HF; Reisner Y
    Hepatology; 2000 Feb; 31(2):480-7. PubMed ID: 10655274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
    Xu DZ; Wang XY; Shen XL; Gong GZ; Ren H; Guo LM; Sun AM; Xu M; Li LJ; Guo XH; Zhen Z; Wang HF; Gong HY; Xu C; Jiang N; Pan C; Gong ZJ; Zhang JM; Shang J; Xu J; Xie Q; Wu TF; Huang WX; Li YG; Xu J; Yuan ZH; Wang B; Zhao K; Wen YM;
    J Hepatol; 2013 Sep; 59(3):450-6. PubMed ID: 23669281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection.
    Zhang JM; Xu Y; Wang XY; Yin YK; Wu XH; Weng XH; Lu M
    Clin Infect Dis; 2007 May; 44(9):1161-9. PubMed ID: 17407033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.
    Lian M; Zhou X; Wei L; Qiu S; Zhou T; Li L; Gu X; Luo M; Zheng X
    Virol J; 2007 Sep; 4():93. PubMed ID: 17892580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional analysis of immune-related genes in dendritic cells from hepatitis B surface antigen (HBsAg)-positive transgenic mice and regulation of Fc gamma receptor IIB by HBsAg-anti-HBs complex.
    Yao X; Wang XY; Zhao C; Sun SH; Meng ZF; Zhang JM; Xu JQ; Xie YH; Yuan ZH; Wen YM
    J Med Virol; 2011 Jan; 83(1):78-87. PubMed ID: 21108342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune response for phase I clinical trial of a hepatitis B immunogenic complex therapeutic vaccine, YIC].
    Liu SA; Xu DZ; Zhang JP; Huang KL; Yao J; Xu LF; Yuan ZH; Wen YM
    Zhonghua Gan Zang Bing Za Zhi; 2006 Feb; 14(2):89-92. PubMed ID: 16494774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B.
    Vassilopoulos D; Rapti I; Nikolaou M; Hadziyannis E; Hadziyannis SJ
    J Viral Hepat; 2008 Nov; 15(11):817-26. PubMed ID: 18554242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection.
    Jang JS; Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Kim DJ; Lee MS; Park CK; Jeong BH; Kim YS; Jang MK
    J Med Virol; 2009 Sep; 81(9):1531-8. PubMed ID: 19623669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of hepatitis B surface antigen-pulsed dendritic cells in patients with chronic hepatitis B.
    Akbar SM; Furukawa S; Horiike N; Abe M; Hiasa Y; Onji M
    J Viral Hepat; 2011 Jun; 18(6):408-14. PubMed ID: 20487261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
    Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virus-specific T cell immune response in children and adolescents with chronic hepatitis B virus infection.
    Fischler B; Nyström J; Björnsdottir T; Lindh G; Hultgren C
    J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):75-83. PubMed ID: 17592368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with recombinant HBsAg-HBIG complex in healthy adults.
    Xu DZ; Huang KL; Zhao K; Xu LF; Shi N; Yuan ZH; Wen YM
    Vaccine; 2005 Apr; 23(20):2658-64. PubMed ID: 15780449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.